EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome

Drosos, George C., Vedder, Daisy, Houben, Eline, Boekel, Laura, Atzeni, Fabiola, Badreh, Sara, Boumpas, Dimitrios T., Brodin, Nina, Bruce, Ian N., Gonzalez-Gay, Miguel Angel, Jacobsen, Soren, Kerekes, Gyorgy, Marchiori, Francesca, Mukhtyar, Chetan, Ramos-Casals, Manuel, Sattar, Naveed, Schreiber, Karen, Sciascia, Savino, Svenungsson, Elisabet, Szekanecz, Zoltan, Tausche, Anne-Kathrin, Tyndall, Alan, van Halm, Vokko, Voskuyl, Alexandre, Macfarlane, Gary J., Ward, Michael M., Nurmohamed, Michael T. and Tektonidou, Maria G. (2022) EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Annals of the Rheumatic Diseases. ISSN 0003-4967

[img]
Preview
PDF (Accepted manuscript) - Accepted Version
Download (380kB) | Preview

Abstract

Objective To develop recommendations for cardiovascular risk (CVR) management in gout, vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Methods Following European League against Rheumatism (EULAR) standardised procedures, a multidisciplinary task force formulated recommendations for CVR prediction and management based on systematic literature reviews and expert opinion. Results Four overarching principles emphasising the need of regular screening and management of modifiable CVR factors and patient education were endorsed. Nineteen recommendations (eleven for gout, vasculitis, SSc, MCTD, myositis, SS; eight for SLE, APS) were developed covering three topics: (1) CVR prediction tools; (2) interventions on traditional CVR factors and (3) interventions on disease-related CVR factors. Several statements relied on expert opinion because high-quality evidence was lacking. Use of generic CVR prediction tools is recommended due to lack of validated rheumatic diseases-specific tools. Diuretics should be avoided in gout and beta-blockers in SSc, and a blood pressure target

Item Type: Article
Uncontrolled Keywords: autoimmune diseases,cardiovascular diseases,lupus erythematosus,systemic,systemic vasculitis,antiphospholipid syndrome,giant-cell arteritis,c-reactive protein,coronary-heart-disease,myocardial-infarction,vascular events,gout,mortality,predictors,cohort,damage,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: LivePure Connector
Date Deposited: 16 Feb 2022 12:30
Last Modified: 29 Apr 2022 00:39
URI: https://ueaeprints.uea.ac.uk/id/eprint/83522
DOI: 10.1136/annrheumdis-2021-221733

Actions (login required)

View Item View Item